DALMASSO A P, MARTINEZ C, SJODIN K, GOOD R A
J Exp Med. 1963 Dec 1;118(6):1089-109. doi: 10.1084/jem.118.6.1089.
The immunologic competence of spleen cells of mice, as assessed by their graft versus host capabilities, increases to 35 days of age and beyond. Thymectomy at any point along this continuum of development produces "immunologic arrest;" the peripheral lymphoid tissues of such mice do not show significant increases in activity as the animals mature, nor is there appreciable loss of activity up to 6 months after surgery. Adult spleen cells from mice thymectomized at 1 to 24 hours of age have a greatly reduced ability to induce runt disease. Five million spleen cells from immunologically mature animals will uniformly cause fatal runt disease in neonatal recipients, but this same number of cells from neonatally thymectomized animals produces almost no runt disease. When the dosage of cells from neonatally thymectomized C(57)Bl mice is increased to 20 million, about half of the A recipients develop runt disease. Thus, the defect is a quantitative one. Spleen cells from neonatally thymectomized mice will induce tolerance of skin grafts from the donor strain. In one recalcitrant strain combination, C(57)Bl to A, use of spleen cells from neonatally thymectomized donors as the tolerance-inducing inoculum permits survival of the recipients, which usually die with severe runt disease, but does not induce tolerance. Cell free extracts of spleen and thymus tissue, including "promine" of Szent-Gyorgyi et al., did not affect the runting syndrome or the immunologic reactivity of neonatally thymectomized mice. When syngeneic thymic tissue is grafted into neonatally thymectomized mice, or the animals are given viable syngeneic spleen or thymus cells, the majority of the animals escape the early mortality characteristic of this group. Administration of syngeneic spleen cells from adult donors and grafting of syngeneic neonatal thymus provide restoration of homograft immunity and graft versus host reactivity of the peripheral lymphoid tissues in most of the neonatally thymectomized animals. Thymus cells rarely provide significant restoration of these parameters. Allogeneic thymus grafts also restore neonatally thymectomized mice. Such animals are chimeric: the immunologically competent cells of their peripheral lymphoid tissues are chiefly of host origin as determined by the discriminant spleen assay, but in many instances a significant donor component is also demonstrable in this system. These chimeric animals accept skin grafts from both donor and host strains. A degree of reconstitution has also been attained by grafting of allogeneic adult spleen in neonatally thymectomized animals. The discriminant spleen assay indicates that cells of the donor strain predominate in the peripheral lymphoid tissues of such mice.
通过小鼠脾细胞的移植物抗宿主能力评估,其免疫能力在35日龄及以后会增强。在这一连续发育过程中的任何时间点进行胸腺切除都会导致“免疫停滞”;此类小鼠的外周淋巴组织不会随着动物成熟而出现活性显著增加的情况,术后6个月内也没有明显的活性丧失。1至24小时龄时接受胸腺切除的成年小鼠脾细胞诱导矮小病的能力大大降低。来自免疫成熟动物的500万个脾细胞会一致地在新生受体中引发致命的矮小病,但来自新生期胸腺切除动物的相同数量的细胞几乎不会引发矮小病。当来自新生期胸腺切除的C(57)Bl小鼠的细胞剂量增加到2000万个时,约一半的A受体出现矮小病。因此,这种缺陷是数量上的。来自新生期胸腺切除小鼠的脾细胞会诱导对供体品系皮肤移植的耐受性。在一种顽固的品系组合,即C(57)Bl到A中,使用来自新生期胸腺切除供体的脾细胞作为诱导耐受性的接种物可使受体存活,这些受体通常会死于严重的矮小病,但不会诱导耐受性。脾和胸腺组织的无细胞提取物,包括Szent-Gyorgyi等人的“促腺嘌呤”,不会影响新生期胸腺切除小鼠的矮小综合征或免疫反应性。当将同基因胸腺组织移植到新生期胸腺切除的小鼠中,或者给动物注射有活力的同基因脾或胸腺细胞时,大多数动物可避免该组动物特有的早期死亡。给予成年供体的同基因脾细胞以及移植同基因新生胸腺可使大多数新生期胸腺切除动物的外周淋巴组织恢复同种异体移植免疫和移植物抗宿主反应性。胸腺细胞很少能显著恢复这些参数。同种异体胸腺移植也能使新生期胸腺切除的小鼠恢复。此类动物是嵌合体:通过鉴别性脾测定法确定,其外周淋巴组织中具有免疫活性的细胞主要来源于宿主,但在许多情况下,该系统中也可显示出显著的供体成分。这些嵌合体动物接受来自供体和宿主品系的皮肤移植。通过将同种异体成年脾移植到新生期胸腺切除的动物中也实现了一定程度的重建。鉴别性脾测定法表明,供体品系的细胞在这类小鼠的外周淋巴组织中占主导地位。